Dianthus Therapeutics

DNTH

Market cap $1.47B

Overview Fund Activity

37.04 USD

-0.12

0.32%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

37.04

0.00

0%

1 day

-0.32%

5 days

16.73%

1 month

78.59%

3 months

103.29%

6 months

68.59%

Year to date

59.66%

1 year

40.2%

5 years

-71.06%

10 years

-84.06%

About: Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Employees: 78

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

369% more call options, than puts

Call options by funds: $2.68M | Put options by funds: $572K

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

6% more capital invested

Capital invested by funds: $685M [Q1] → $729M (+$43.1M) [Q2]

4.22% more ownership

Funds ownership: 117.38% [Q1] → 121.6% (+4.22%) [Q2]

4% more funds holding

Funds holding: 98 [Q1] → 102 (+4) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

28% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 40

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$40

8% upside

Avg. target

$63

71% upside

High target

$100

170% upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Stifel Alex Thompson	$65	Buy Maintained	12 Sep 2025
Wedbush Laura Chico	$44	Outperform Maintained	12 Sep 2025
Raymond James Steven Seedhouse	$63	Outperform Reiterated	9 Sep 2025
Guggenheim Yatin Suneja	$100	Buy Maintained	9 Sep 2025
Baird Joel Beatty	$67	Outperform Maintained	9 Sep 2025
HC Wainwright & Co. Swayampakula Ramakanth	$40	Buy Reiterated	8 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about DNTH published over the past 30 days

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced that it closed its previously announced underwritten public offering of 7,627,879 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,140,000 shares, at a public offering price of $33.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,112,121 shares of its common stock at a public offering price of $32.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering were approximately $288 million before deducting underwriting discounts and commissions and other offering expenses payable by Dianthus. All of the securities were offered by Dianthus.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced the pricing of its previously announced upsized underwritten public offering of 6,487,879 shares of its common stock at a public offering price per share of $33.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,112,121 shares of its common stock at a public offering price of $32.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $251 million before deducting underwriting discounts and commissions and other offering expenses payable by Dianthus, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on September 11, 2025, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,140,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call

Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call Company Participants Marino Garcia - President, CEO & Director Simrat Randhawa - Chief Medical Officer Conference Call Participants Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Yaron Werber - TD Cowen, Research Division Myles Minter - William Blair & Company L.L.C., Research Division Presentation Operator Good morning, and welcome to the Dianthus Therapeutics Conference Call.

Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced that it has commenced an underwritten public offering of $150 million of its shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Dianthus.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

Investors Business Daily

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Shares of Dianthus Therapeutics surged Monday after the company's autoimmune disease treatment succeeded in a midstage study.

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13 Claseprubart demonstrated a rapid and sustained onset of action, with both doses achieving statistically significant improvements in MG-ADL and QMG scores at Week 1 Claseprubart 300mg Q2W dose was also statistically significant and clinically meaningful across other key efficacy endpoints, including Minimal Symptom Expression (MSE), Myasthenia Gravis Composite (MGC) Score and the Myasthenia Gravis Quality of Life Scale (MG-QoL-15r) Both 300mg and 600mg doses of claseprubart were comparable across key efficacy endpoints, supporting its target product profile of a single, convenient 300mg/2mL self-administered, subcutaneous autoinjector dosed once every two weeks Claseprubart had a favorable safety profile with no related serious infections, clinical symptoms of emergent autoimmune disease, or drug-related serious adverse events or discontinuations, supporting its target product profile of no Boxed Warning or REMS for meningococcal infections Phase 3 gMG trial evaluating 300mg/2mL Q2W and Q4W vs. placebo anticipated to initiate in 2026 Investor conference call and webcast to be held today, September 8, 2025 at 8:00 a.m.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

Zacks Investment Research

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.51 per share a year ago.

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

The Motley Fool

Dianthus (DNTH) Q2 Loss Widens 80%

Dianthus Therapeutics (DNTH -6.08%), a clinical-stage biotech developing therapies for autoimmune neuromuscular diseases, reported second quarter results on August 7, 2025. Net loss per share (GAAP) was $(0.88).

Dianthus (DNTH) Q2 Loss Widens 80%

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE'26

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™